1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6B8A20EFE71CB4D9A002587120021F383
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-field-medical-excellence-optimizing-structure-resourcing?opendocument
18
19opendocument
203.239.58.199
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Medical Science Liaison

Field Medical Excellence: Optimizing Structure and Resourcing

ID: 5684


Features:

4 Info Graphics

10 Data Graphics

140+ Metrics


Pages/Slides: 20


Published: 2021


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Field Medical Excellence: Optimizing Structure and Resourcing”

STUDY OVERVIEW

In the COVID era where traditional approaches to physician access are being rewritten on the fly, Medical Affairs leaders need to redefine the structure and roles of their field medical teams to ensure effectiveness.

Best Practices, LLC conducted this benchmarking research to identify competitive field medical team staffing and resource levels, and optimal field medical team structures in key global markets.

Field Medical and Medical Affairs leaders can refer to this study to benchmark their staffing and resource allocations against industry standards.

KEY TOPICS

  • Field Team Staffing
  • Field Team Resourcing
  • Field Medical Team Organizational Structure

KEY METRICS

  • How do you expect the size of your field medical team to change in the next 24 months for the indicated therapeutic area?
  • On average, what percentage of the peak MSL team size are assigned to support a product at each phase of the typical product lifecycle?
  • What is the approximate annual total travel and entertainment (T&E) budget allocated to an MSL in each of the listed countries/regions?
  • To what part of the organization do your MSLs directly report?
  • How are MSLs and other field-based medical staff assigned across your organization?
  • How do your local affiliate office(s) provide field medical team support across the region?
  • How effective are each of the of the listed field-based resources that your Medical Affairs organization has deployed to support your treatment portfolio?

SAMPLE KEY FINDINGS

  • Field staff almost always work within Medical organization, but may report directly to country, TA or other units: Within nearly all surveyed organizations, MSLs are aligned to the Medical organization. That said, MSLs are slightly more likely to report to a global Therapeutic Area unit (rather than Global Medical), and MSL managers and field directors more often report to the Country unit than any other part of the company.

METHODOLOGY

Best Practices, LLC engaged 100 Field Medical and Medical Affairs leaders from 62 biopharmaceutical companies through a benchmarking survey. More than half of research participants serve as Field Medical or Medical Affairs directors, while over 15% of participants serve at the executive level.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Consulting; Medical Device; Manufacturing; Consumer Products; Diagnostic; Health Care; Communications; Clinical Research; Laboratories


Companies Profiled:
Adamas Pharmaceuticals; Alkermes; Alnylam Pharmaceuticals; Amgen; Apellis Pharmaceuticals; Arcutis Biotherapeutics; ASC Therapeutics; Ashfield Healthcare; Astellas; AstraZeneca; Aurinia Pharmaceuticals; Baxter Healthcare; Bayer; BeiGene; BioMarin; Boehringer Ingelheim; Chiesi; Cipla; Clovis Oncology; Curis; Daiichi Sankyo; Dova Pharmaceuticals; Dr Reddy's Laboratories; Eisai; ERYTECH; Eurofarma; Foundation Medicine; GE Healthcare; Gilead Sciences; GlaxoSmithKline ; Greenwich Biosciences; Grifols; Grünenthal; Kartos Therapeutics; Kiniksa Pharmaceuticals; Kyowa Kirin; Legend Biotech; LEO Pharma; Merck; Mesoblast; Miravo Healthcare; NexGen Healthcare Communications; Novartis; Novo Nordisk; OM Pharma; Paratek Pharmaceuticals; Pfizer; Pharmacosmos Therapeutics Inc.; Radius Health; Inc.; Reata Pharmaceuticals; Sanofi; Sanofi Genzyme; Servier; Sunovion; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; Theravance; Travere Therapeutics; Urovant Sciences; Vertex Pharmaceuticals; Vifor Pharma; Zogenix

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.